INSMED Inc (INSM) stock
INSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/3099% above fair value
$119.80−2.06 (-1.69%)
Close on Nov 18, 2026Market cap $26.28BP/E –Yield –
Insmed revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Insmed's revenue for the twelve months ending Sep 30, 2026 was $1.52B, up 240.0% year over year. For fiscal 2025 it was $606.42M, up 66.7% from the year before. The highest annual figure on record is $606.42M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $606.42M | +66.7% |
| FY2024 | Dec 31, 2024 | $363.71M | +19.2% |
| FY2023 | Dec 31, 2023 | $305.21M | +24.4% |
| FY2022 | Dec 31, 2022 | $245.36M | +30.2% |
| FY2021 | Dec 31, 2021 | $188.46M | +14.6% |
| FY2020 | Dec 31, 2020 | $164.41M | +20.5% |
| FY2019 | Dec 31, 2019 | $136.47M | +1287.6% |
| FY2018 | Dec 31, 2018 | $9.84M | – |
| FY2017 | Dec 31, 2017 | $0 | – |
| FY2016 | Dec 31, 2016 | $0 | – |
| FY2015 | Dec 31, 2015 | $0 | -100.0% |
| FY2013 | Dec 31, 2013 | $11.50M | – |
| FY2012 | Dec 31, 2012 | $0 | -100.0% |
| FY2011 | Dec 31, 2011 | $4.42M | -36.2% |
| FY2010 | Dec 31, 2010 | $6.92M | -33.3% |
| FY2009 | Dec 31, 2009 | $10.37M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $524.43M | +268.4% |
| Q2 FY2026 | Jun 30, 2026 | $425.49M | +296.1% |
| Q1 FY2026 | Mar 31, 2026 | $305.96M | +229.6% |
| Q4 FY2025 | Dec 31, 2025 | $263.84M | +152.6% |
| Q3 FY2025 | Sep 30, 2025 | $142.34M | +52.4% |
| Q2 FY2025 | Jun 30, 2025 | $107.42M | +18.9% |
| Q1 FY2025 | Mar 31, 2025 | $92.82M | +22.9% |
| Q4 FY2024 | Dec 31, 2024 | $104.44M | +24.8% |
| Q3 FY2024 | Sep 30, 2024 | $93.43M | +18.2% |
| Q2 FY2024 | Jun 30, 2024 | $90.34M | +17.0% |
| Q1 FY2024 | Mar 31, 2024 | $75.50M | +15.8% |
| Q4 FY2023 | Dec 31, 2023 | $83.69M | +41.1% |
| Q3 FY2023 | Sep 30, 2023 | $79.07M | +16.7% |
| Q2 FY2023 | Jun 30, 2023 | $77.23M | +18.4% |
| Q1 FY2023 | Mar 31, 2023 | $65.21M | +22.8% |
| Q4 FY2022 | Dec 31, 2022 | $59.30M | +5.7% |
| Q3 FY2022 | Sep 30, 2022 | $67.73M | +44.9% |
| Q2 FY2022 | Jun 30, 2022 | $65.22M | +43.8% |
| Q1 FY2022 | Mar 31, 2022 | $53.11M | +32.1% |
| Q4 FY2021 | Dec 31, 2021 | $56.12M | +35.5% |
| Q3 FY2021 | Sep 30, 2021 | $46.76M | +7.1% |
| Q2 FY2021 | Jun 30, 2021 | $45.37M | +6.8% |
| Q1 FY2021 | Mar 31, 2021 | $40.21M | +9.1% |
| Q4 FY2020 | Dec 31, 2020 | $41.42M | -9.4% |
| Q3 FY2020 | Sep 30, 2020 | $43.64M | +12.2% |
| Q2 FY2020 | Jun 30, 2020 | $42.50M | +41.8% |
| Q1 FY2020 | Mar 31, 2020 | $36.86M | +68.3% |
| Q4 FY2019 | Dec 31, 2019 | $45.71M | +364.7% |
| Q3 FY2019 | Sep 30, 2019 | $38.89M | – |
| Q2 FY2019 | Jun 30, 2019 | $29.97M | – |
| Q1 FY2019 | Mar 31, 2019 | $21.90M | – |
| Q4 FY2018 | Dec 31, 2018 | $9.84M | – |
| Q3 FY2018 | Sep 30, 2018 | $0 | – |
| Q2 FY2018 | Jun 30, 2018 | $0 | – |
| Q1 FY2018 | Mar 31, 2018 | $0 | – |
| Q4 FY2017 | Dec 31, 2017 | $0 | – |
| Q3 FY2017 | Sep 30, 2017 | $0 | – |
| Q2 FY2017 | Jun 30, 2017 | $0 | – |
| Q1 FY2017 | Mar 31, 2017 | $0 | – |
| Q4 FY2016 | Dec 31, 2016 | $0 | – |
See a number that looks wrong?